Oncoinvent ASA Reports Trade and Share Lending Following Private Placement
Oncoinvent ASA has announced share transactions and lending related to its recently completed private placement. An investor group participated in the placement and engaged in share lending.
Oslo, Norway – Oncoinvent ASA announced on September 23, 2026, details regarding share trades and lending connected to the company's private placement that concluded on September 22. The private placement involved the issuance of 1,650,000 new shares at a subscription price of NOK 90 per share.
Prior to the share lending arrangements, Hadean Capital I AS, HVentures Capital I AB, and Hadean Growth Fund I AS collectively held 554,327 shares in the company, representing approximately 12.38% of the total shares and votes.
The announcement specifically addresses the share lending activities undertaken by this investor group as part of the private placement. Further details on the terms and impact of these lending arrangements are available in the company's official stock exchange release.
Oncoinvent ASA is a Norwegian pharmaceutical company focused on developing novel treatments for cancer. Its technology platform utilizes targeted alpha therapy, employing radioactive isotopes to treat cancer.
This disclosure is a mandatory notification required by stock exchange regulations concerning significant share transactions and ownership changes.